阿贝拉西单抗抑制因子XI在狒狒活金黄色葡萄球菌脓毒症模型中的保护作用
阿贝拉西单抗组6只全部存活至7天终点,对照组6只中3只在102小时内死亡;治疗组凝血病减轻且无出血迹象,促炎细胞因子降低、中性粒细胞活化减少、内皮完整性得以保持。
要点
- 阿贝拉西单抗组6只狒狒全部存活至7天终点,对照组6只中3只在102小时内死于脓毒症。
- 阿贝拉西单抗减轻脓毒症诱导的凝血病,生化检查和病理分析均未见出血迹象。
- 治疗组促炎细胞因子降低、中性粒细胞活化减少、内皮完整性保持,共同提供器官保护。
核心结论
- 阿贝拉西单抗抑制FXI通过减轻凝血激活、减少炎症和预防器官衰竭提供显著保护。
- 靶向FXI可能通过应对脓毒症复杂病理生理的多个方面成为有前景的治疗策略。
研究设计与样本
- 研究将健康Papio anubis狒狒随机分配到对照组或阿贝拉西单抗治疗组,每组n=6。
- 两组均静脉输注活金黄色葡萄球菌的中位致死剂量(LD50)。
- 治疗组在细菌输注开始后30分钟给予阿贝拉西单抗。
- 监测血液学、凝血、炎症和器官功能参数7天或直至动物出现不可逆器官衰竭迹象。
- 进行蛋白质组学分析以阐明阿贝拉西单抗提供保护的潜在机制。
主要发现
- 阿贝拉西单抗组6只狒狒全部存活至7天终点,对照组6只中3只在102小时内死于脓毒症。
- 阿贝拉西单抗显著减轻脓毒症诱导的凝血病,生化检查和病理分析均未见出血迹象。
- 治疗组动物促炎细胞因子降低、中性粒细胞活化减少、内皮完整性保持,共同提供对抗器官损伤的强有力保护。
- 蛋白质组学分析显示阿贝拉西单抗调节与凝血、炎症和组织损伤相关的通路,有助于改善生存结局。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sepsis remains a major clinical challenge characterized by dysregulated immune response, coagulation abnormalities, and multiorgan failure, leading to high morbidity and mortality. OBJECTIVES: This study investigated the therapeutic potential of abelacimab, a monoclonal antibody targeting the plasma zymogen factor (F)XI, in a new baboon model of Staphylococcus aureus sepsis. METHODS: Healthy Papio anubis baboons were randomly assigned to control or abelacimab treatment groups. Both groups (n = 6, each) were intravenously infused with a median lethal (LD50) dose of live S aureus. The treatment group was administered abelacimab 30 minutes after the onset of bacterial infusion. Hematologic, coagulation, inflammatory, and organ function parameters were monitored for 7 days or until the animal exhibited signs of irreversible organ failure. Proteomic analysis was conducted to elucidate the underlying mechanisms by which abelacimab offered protection. RESULTS: All 6 abelacimab-treated baboons survived until the 7-day endpoint, while 3 out of 6 untreated controls succumbed to sepsis within 102 hours. Abelacimab significantly attenuated sepsis-induced coagulopathy without signs of bleeding, as evidenced by biochemical tests and pathology analysis. Treated animals exhibited decreased proinflammatory cytokines, diminished neutrophil activation, and preservation of endothelial integrity, collectively conferring robust protection against organ damage. Proteomic analysis revealed that abelacimab modulated pathways related to coagulation, inflammation, and tissue injury, contributing to improved survival outcomes. CONCLUSION: FXI inhibition by abelacimab offers significant protection by attenuating activation of coagulation, reducing inflammation, and preventing organ failure. Targeting FXI may be a promising therapeutic strategy for managing sepsis by addressing multiple facets of its complex pathophysiology.
引用
- Silasi R, Keshari RS, Abe T, et al. Protective effects of factor XI inhibition by abelacimab in a baboon model of live Staphylococcus aureus sepsis. J Thromb Haemost. 2025. PMID: 40582699. doi:10.1016/j.jtha.2025.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。